Brickell is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated therapeutics for the treatment of dermatologic, autoimmune, and other debilitating diseases.
Our current pipeline aims to disrupt existing treatment paradigms and features new molecular entities with best-in-class and first-in-class potential targeting medical dermatology, autoimmune disorders and neuroinflammatory conditions.
Hyperhidrosis is a life-altering condition of sweating beyond what is physiologically required to maintain normal thermal regulation and is estimated to affect 15.3 million, or 4.8%, of the U.S. population.
The immune system is a tightly regulated network that maintains a balance of immune homeostasis under healthy conditions. However, in patients with autoimmune disease and chronic inflammation, this equilibrium becomes disrupted.